Anavex Life Sciences (AVXL) Non-Current Deffered Revenue (2021 - 2025)
Anavex Life Sciences recorded quarterly Non-Current Deffered Revenue of $805000.0 in Q4 2025, little changed quarter-over-quarter from $805000.0 in Q3 2025.
Anavex Life Sciences' Non-Current Deffered Revenue history runs 5 years deep, the most recent figure standing at $805000.0 for Q4 2025.
- In Q4 2025, Non-Current Deffered Revenue changed N/A year-over-year to $805000.0; the TTM figure through Dec 2025 stood at $805000.0 (changed N/A YoY), while the FY2025 annual figure was $805000.0, down 4.39% from the prior year.
- Non-Current Deffered Revenue came in at $805000.0 for Q4 2025 at Anavex Life Sciences, roughly flat from $805000.0 in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $917000.0 in Q3 2023 to a low of $443831.0 in Q3 2021.
- A 5-year average of $709471.8 and a median of $805000.0 in 2025 frame the typical range for Non-Current Deffered Revenue.
- Across the five-year window, Non-Current Deffered Revenue jumped 106.53% in 2023 and dropped 8.18% in 2024, its largest moves.
- Anavex Life Sciences' Non-Current Deffered Revenue stood at $443831.0 in 2021, then grew by 0.04% to $444000.0 in 2022, then soared by 106.53% to $917000.0 in 2023, then dropped by 8.18% to $842000.0 in 2024, then retreated by 4.39% to $805000.0 in 2025.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $805000.0, $805000.0, and $842000.0 for Q4 2025, Q3 2025, and Q3 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 225.10 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - | 805,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 805,000.00 |
| Sep 30, 2025 | 805,000.00 |
| Sep 30, 2024 | 842,000.00 |
| Sep 30, 2023 | 917,000.00 |
| Sep 30, 2022 | 444,000.00 |
| Sep 30, 2021 | 443,831.00 |